Skip to main content
. Author manuscript; available in PMC: 2015 Jan 9.
Published in final edited form as: Am J Cancer Ther Pharmacol. 2014 Sep 7;2(1):21–32.

Table 3.

Cardiac and other ≥ Grade 2 Adverse Events

n (%)
Bradycardia, asymptomatic 2 (12.5%)
EKG changes* 3 (18.75%)
Hyperglycemia 1 (6.25%)
Lower back pain¥ 1 (6.25%)
*

8/16 showed dig effects, 3/16 ST stagging but no concerning arrhythmias or other ECG abnormalities to suggest digoxin toxicity.

¥

possible AE